D.Western Therapeutics Institute, Inc. (JP:4576)
:4576
Top Page
D.Western Therapeutics Institute
(4576)
Select Model
Select Model
Rating:43Neutral
Price Target:
¥89.00
▼(-15.24% Downside)
Action:ReiteratedDate:03/24/26
The score is primarily constrained by weak financial performance driven by persistent losses and continued cash burn, despite improved leverage and narrowing losses. Technicals add further pressure with the stock trading below all major moving averages and negative MACD. Valuation provides limited support because the negative P/E reflects unprofitability and no dividend yield is available.
Positive Factors
High Gross Margins
Sustained very high gross margins indicate strong unit economics and pricing power for the core product set. This creates durable capacity to fund R&D and SG&A as revenue scales, improving the path to sustainable profitability once fixed costs are absorbed.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow means the business cannot self-fund operations and relies on external capital. This structural cash burn elevates dilution or refinancing risk and constrains the company's ability to invest aggressively without securing new funding.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained very high gross margins indicate strong unit economics and pricing power for the core product set. This creates durable capacity to fund R&D and SG&A as revenue scales, improving the path to sustainable profitability once fixed costs are absorbed.
Read all positive factors
D.Western Therapeutics Institute (4576) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.10B
Dividend YieldN/A
Average Volume (3M)623.89K
Price to Earnings (P/E)―
Beta (1Y)0.24
Revenue Growth-9.39%
EPS Growth24.12%
CountryJP
Employees21
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.44
Shares Outstanding54,831,710
10 Day Avg. Volume615,690
30 Day Avg. Volume623,886
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.21
Price to Sales (P/S)11.87
P/FCF Ratio-9.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
D.Western Therapeutics Institute Business Overview & Revenue Model
Company Description
D.Western Therapeutics Institute (4576) is a biotechnology company focused on developing innovative therapeutic solutions for various medical conditions. Operating primarily in the healthcare sector, the company specializes in research and develop...
How the Company Makes Money
null...
D.Western Therapeutics Institute Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 421.06M | 387.62M | 471.58M | 428.36M | 448.10M | 414.42M |
| Gross Profit | 363.02M | 301.24M | 424.74M | 391.70M | 420.53M | 394.32M |
| EBITDA | -1.03B | -572.35M | -1.23B | -775.59M | -390.75M | -110.03M |
| Net Income | -1.09B | -632.09M | -1.29B | -812.41M | -429.69M | -149.00M |
Balance Sheet | ||||||
| Total Assets | 1.51B | 2.17B | 1.67B | 2.37B | 2.96B | 2.46B |
| Cash, Cash Equivalents and Short-Term Investments | 1.05B | 1.71B | 1.13B | 1.87B | 2.33B | 1.93B |
| Total Debt | 517.95M | 605.18M | 797.98M | 885.12M | 967.69M | 340.00M |
| Total Liabilities | 628.89M | 734.01M | 935.57M | 1.09B | 1.08B | 427.72M |
| Stockholders Equity | 884.57M | 1.44B | 733.87M | 1.28B | 1.86B | 2.01B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -496.54M | -1.31B | -601.76M | -364.58M | -179.21M |
| Operating Cash Flow | 0.00 | -493.79M | -1.30B | -586.82M | -354.77M | -176.31M |
| Investing Cash Flow | 0.00 | -2.45M | -10.01M | -15.25M | -139.89M | -111.15M |
| Financing Cash Flow | 0.00 | 1.08B | 567.63M | 134.47M | 867.30M | -104.46M |
D.Western Therapeutics Institute Technical Analysis
Neutral
105.00
Price Trends
98.62
Negative
99.53
Negative
107.25
Negative
Market Momentum
-1.45
Negative
49.49
Neutral
29.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4576, the sentiment is Neutral. The current price of 105 is above the 20-day moving average (MA) of 96.00, above the 50-day MA of 98.62, and below the 200-day MA of 107.25, indicating a neutral trend. The MACD of -1.45 indicates Negative momentum. The RSI at 49.49 is Neutral, neither overbought nor oversold. The STOCH value of 29.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4576.
D.Western Therapeutics Institute Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥17.31B | 120.78 | ― | ― | 1.24% | -33.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥49.01B | -13.30 | ― | ― | -82.33% | 47.73% | |
49 Neutral | ¥11.31B | -8.14 | ― | ― | -42.49% | -2.37% | |
45 Neutral | ¥19.24B | -11.30 | ― | ― | ― | 11.34% | |
43 Neutral | ¥5.10B | -7.28 | -86.84% | ― | -9.39% | 24.12% | |
43 Neutral | ¥159.03B | -35.18 | -253.07% | ― | ― | -12.69% |
* Healthcare Sector Average
JP:4576
D.Western Therapeutics Institute
93.00
-11.00
-10.58%
JP:4592
SanBio Co
2,038.00
364.00
21.74%
JP:4593
Healios KK
363.00
127.00
53.81%
JP:4599
StemRIM Inc.
307.00
37.00
13.70%
JP:4978
ReproCELL Inc.
182.00
51.00
38.93%
JP:7776
CellSeed Inc.
291.00
-234.00
-44.57%
D.Western Therapeutics Institute Corporate Events
D. Western Therapeutics Completes Global Phase III Follow-Up for Fuchs Drug K-321
Mar 19, 2026
D. Western Therapeutics Institute said the observation period has now been completed for all global phase III clinical studies of K-321, an ophthalmic solution for Fuchs endothelial corneal dystrophy licensed to Kowa Company, Ltd. The trials, cond...
D.Western Therapeutics Narrows Loss but Warns of Deeper Red Ink in 2026
Feb 13, 2026
D.Western Therapeutics Institute reported a 17.8% decline in net sales to ¥387 million for the year ended December 31, 2025, but significantly narrowed its net loss to ¥632 million from ¥1,290 million a year earlier, as operating ca...
D. Western Therapeutics Outlines FY12/25 Results and FY12/26 Outlook
Feb 13, 2026
D. Western Therapeutics Institute has released briefing materials for its fiscal year ending December 2025, outlining financial results, business progress, and forecasts for the next fiscal year. The document signals continued development of its t...
D.Western Therapeutics Narrows Losses but Forecasts Deeper Red Ink in 2026
Feb 13, 2026
D.Western Therapeutics Institute reported a 17.8% decline in net sales to ¥387 million for the year ended December 31, 2025, although its net loss narrowed to ¥632 million from ¥1,290 million a year earlier. The company’s equi...
D. Western Therapeutics Institute Outlines FY2025 Results and FY2026 Outlook
Feb 13, 2026
D. Western Therapeutics Institute has released briefing materials for its fiscal year ending December 2025, outlining financial results, business progress, and its forecast for fiscal 2026. The document signals continued efforts to communicate per...
DWTI’s Glaucoma Combination Eye Drop GLA-ALPHA Debuts in Singapore Through Kowa
Jan 13, 2026
D. Western Therapeutics Institute announced that its partner Kowa has begun sales in Singapore of GLA-ALPHA Combination Ophthalmic Solution, a fixed-dose eye drop that combines the company’s in-house discovered Rho-kinase inhibitor ripasudil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.